Genome-wide DNA methylation signature predict clinical benefit of bevacizumab in non-small cell lung cancer

Genome-wide DNA methylation signature predict clinical benefit of bevacizumab in non-small cell lung cancer

Abstract Background The efficacy of bevacizumab in non-small cell lung cancer (NSCLC) patients is unsatisfactory, and the selection of suitable patients is still challenging. Given the epigenetic modifications can contribute to an aberrant regulation of angiogenesis and microenvironment, we investig...

Full description

Bibliographic Details
Main Authors: Butuo Li, Chao Jiang, Yiyue Xu, Xinyu Fan, Linlin Yang, Bing Zou, Bingjie Fan, Linlin Wang
Format: Article
Language:English
Published: BMC 2022-07-01
Series:BMC Cancer
Subjects:
Bevacizumab
Non-small cell lung cancer
Methylation
Signature
Predictive
Online Access:https://doi.org/10.1186/s12885-022-09918-1

Internet

https://doi.org/10.1186/s12885-022-09918-1

Similar Items